Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 12
Venture Financing 13
Orchard Therapeutics Raises USD150 Million in Series C Financing 13
Orchard Therapeutics Raises USD110 Million in Series B Financing 16
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 18
Partnerships 19
Orchard Therapeutics and MolMed Expand Collaboration Agreement 19
Orchard Therapeutics Enters into Agreement with Genethon 20
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 21
Licensing Agreements 23
Orchard Therapeutics Enters into Licensing Agreement with University of Manchester 23
Orchard Therapeutics Enters into Licensing Agreement with Oxford BioMedica 24
Orchard Therapeutics Ltd – Key Competitors 25
Orchard Therapeutics Ltd – Key Employees 26
Orchard Therapeutics Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Aug 28, 2018: Orchard Therapeutics expands leadership team with appointments of head of corporate communications and head of human resources 28
Aug 02, 2018: Orchard Therapeutics appoints Jon Ellis to Board of Directors 29
Jul 09, 2018: Orchard Therapeutics Names Joanne Beck As Board Director 30
Jun 29, 2018: Orchard Therapeutics Appoints Jim Geraghty as Chairman of its Board of Directors 31
Jun 07, 2018: Orchard Therapeutics Appoints Marc Dunoyer And Charlie Rowland As Board Directors 32
Mar 21, 2018: Orchard Therapeutics Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer and General Counsel 33
Feb 21, 2018: Orchard Therapeutics Appoints Dr. Harry Malech to Scientific Advisory Board 34
Jan 17, 2018: Orchard Therapeutics Appoints Frank Thomas as Chief Financial Officer and Chief Business Officer 35
Aug 10, 2017: Orchard Therapeutics appoints Mark Rothera as CEO 36
Government and Public Interest 37
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 37
Product News 39
10/23/2017: NICE approves gene therapy for rare ‘bubble baby syndrome’ 39
01/03/2018: NICE final draft guidance recommends gene therapy for rare ‘bubble baby syndrome’ 40
Product Approvals 41
May 03, 2018: Orchard Therapeutics OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy 41
Jul 24, 2017: Orchard Therapeutics announces that OTL-101 has Received a Rare Paediatric Disease Designation 42
Other Significant Developments 43
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orchard Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Orchard Therapeutics Acquires Rare Disease Gene Therapy Portfolio from GlaxoSmithKline 12
Orchard Therapeutics Raises USD150 Million in Series C Financing 13
Orchard Therapeutics Raises USD110 Million in Series B Financing 16
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 18
Orchard Therapeutics and MolMed Expand Collaboration Agreement 19
Orchard Therapeutics Enters into Agreement with Genethon 20
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 21
Orchard Therapeutics Enters into Licensing Agreement with University of Manchester 23
Orchard Therapeutics Enters into Licensing Agreement with Oxford BioMedica 24
Orchard Therapeutics Ltd, Key Competitors 25
Orchard Therapeutics Ltd, Key Employees 26
Orchard Therapeutics Ltd, Subsidiaries 27
List of Figures
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orchard Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer